Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 1999
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.
Epistemonikos ID: 03c7bde286995dc10cfd1485a65bac02227ef847
First added on: Dec 01, 2021